Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 13/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 13/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.32 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.32 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18726574 | 1.00 | HDAC1 (0.37) | HDAC1HDAC2LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL29353376 | 1.00 | HDAC1 (0.37) | HDAC1HDAC2LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL18726765 | 0.94 | HDAC1 (0.40) | HDAC1HDAC2LMNAALDH1A1EHMT2 | |
| SCHEMBL18896133 | 0.90 | HDAC1 (0.36) | HDAC1HDAC2LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL9904994 | 0.90 | HDAC1 (0.36) | HDAC1HDAC2LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL18656418 | 0.87 | HDAC1 (0.36) | HDAC1HDAC2LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL15994284 | 0.87 | HPGD (0.38) | HDAC1HDAC2LMNAALDH1A1MAPT | |
| SCHEMBL18052247 | 0.86 | HDAC1 (0.37) | HDAC1HDAC2LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL29427565 | 0.86 | HDAC1 (0.34) | HDAC1HDAC2 | |
| SCHEMBL19188153 | 0.85 | HDAC1 (0.36) | HDAC1HDAC2ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1225 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12428477-B2 | Antibody-drug conjugates comprising anti-TM4SF1 antibodies and methods of using the same | ANGIEX, INC. (US) | 2025-09-30 | — | — | US | claimed |
| US-20240226312-A1 | TREATMENT OF CANCER IN PATIENTS WITH SOLUBLE FR-ALPHA | IMMUNOGEN, INC. (US) | 2024-07-11 | — | — | US | claimed |
| US-20240132585-A1 | FOLATE RECEPTOR 1 ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREOF | IMMUNOGEN, INC. (US) | 2024-04-25 | — | — | US | claimed |
| EP-4347661-A1 | TREATMENT OF CANCER IN PATIENTS WITH SOLUBLE FR-ALPHA | ImmunoGen, Inc. (US) | 2024-04-10 | — | — | EP | claimed |
| EP-3218410-B1 | ANTIBODY DRUG CONJUGATES | NOVARTIS AG (CH) | 2024-03-27 | — | — | EP | claimed |
| EP-4313009-A1 | MAYTANSINE-ANTIBODY CONJUGATES AND METHODS OF USING SAME | Angiex, Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| EP-4309671-A2 | METHODS FOR INCREASING EFFICACY OF FOLR1 CANCER THERAPY | ImmunoGen, Inc. (US) | 2024-01-24 | — | — | EP | claimed |
| US-20230364252-A1 | METHODS FOR FORMULATING ANTIBODY DRUG CONJUGATE COMPOSITIONS | IMMUNOGEN SWITZERLAND GMBH (CH) | 2023-11-16 | — | — | US | claimed |
| EP-3636279-B1 | METHODS FOR INCREASING EFFICACY OF FOLR1 CANCER THERAPY | IMMUNOGEN INC (US) | 2023-09-13 | — | — | EP | claimed |
| US-11744900-B2 | Preparation of maytansinoid antibody conjugates by a one-step process | IMMUNOGEN, INC. (US) | 2023-09-05 | — | — | US | claimed |
| WO-2012058592-A2 | NON-ANTAGONISTIC EGFR-BINDING MOLECULES AND IMMUNOCONJUGATES THEREOF | IMMUNOGEN, INC. (US) | 2012-05-03 | — | — | WO | claimed |
| WO-2012019024-A2 | HER3-BINDING MOLECULES AND IMMUNOCONJUGATES THEREOF | IMMUNOGEN, INC. (US) | 2012-02-09 | — | — | WO | claimed |
| US-20120009181-A1 | Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof | IMMUNOGEN SWITZERLAND GMBH (CH) | 2012-01-12 | — | — | US | claimed |
| US-20110256153-A1 | CD37-Binding Molecules and Immunoconjugates Thereof | DEBIOPHARM INTERNATIONAL, S.A. (CH) | 2011-10-20 | — | — | US | claimed |
| WO-2011112978-A1 | CD37-BINDING MOLECULES AND IMMUNOCONJUGATES THEREOF | IMMUNOGEN, INC. (US) | 2011-09-15 | — | — | WO | claimed |
| WO-2011106528-A1 | FOLATE RECEPTOR 1 ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREOF | IMMUNOGEN, INC. (US) | 2011-09-01 | — | — | WO | claimed |
| WO-2011100403-A1 | CD20 ANTIBODIES AND USES THEREOF | IMMUNOGEN, INC (US) | 2011-08-18 | — | — | WO | claimed |
| WO-2011100398-A1 | CD20 ANTIBODIES AND USES THEREOF | IMMUNOGEN, INC. (US) | 2011-08-18 | — | — | WO | claimed |
| US-20110195021-A1 | CD20 ANTIBODIES AND USES THEREOF | IMMUNOGEN INC. (US) | 2011-08-11 | — | — | US | claimed |
| US-20110195022-A1 | CD20 ANTIBODIES AND USES THEREOF | IMMUNOGEN INC. (US) | 2011-08-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12428477-B2 | Antibody-drug conjugates comprising anti-TM4SF1 antibodies and methods of using the same | TM9SF4, TM9SF2, TM9SF3 | HDAC1 4391/4885HDAC2 4612/4885LMNA 2873/4885 |
| US-20110256153-A1 | CD37-Binding Molecules and Immunoconjugates Thereof | SIGLEC7, FUT7, CD2BP2 | HDAC1 2977/4885HDAC2 3109/4885LMNA 4838/4885 |
| US-20120009181-A1 | Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof | FOLR1, FOLR2, DHFR | HDAC1 3469/4885HDAC2 4693/4885LMNA 4830/4885 |
| US-20110195021-A1 | CD20 ANTIBODIES AND USES THEREOF | BCL9, BCL9L, BCL6B | HDAC1 4483/4885HDAC2 4462/4885LMNA 469/4885 |
| US-20240132585-A1 | FOLATE RECEPTOR 1 ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREOF | FOLR1, FOLR2, DHFR | HDAC1 3469/4885HDAC2 4693/4885LMNA 4830/4885 |
| US-20240226312-A1 | TREATMENT OF CANCER IN PATIENTS WITH SOLUBLE FR-ALPHA | FOLR1, FOLR2, FRS2 | HDAC1 3746/4885HDAC2 4489/4885LMNA 4318/4885 |
| US-20110195022-A1 | CD20 ANTIBODIES AND USES THEREOF | BCL9, BCL9L, BCL6B | HDAC1 4483/4885HDAC2 4462/4885LMNA 469/4885 |
| US-11744900-B2 | Preparation of maytansinoid antibody conjugates by a one-step process | CD47, CD22, CLSPN | HDAC1 3862/4885HDAC2 4221/4885LMNA 2916/4885 |
| US-20230364252-A1 | METHODS FOR FORMULATING ANTIBODY DRUG CONJUGATE COMPOSITIONS | FCGRT, FCGR1A, FCGR3B | HDAC1 3644/4885HDAC2 3075/4885LMNA 3572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.